Raxone fachinformation
WebNov 8, 2024 · Below is a text only representation of the Patient Information Leaflet (ePIL). The text only version may be available in large print, Braille or audio CD . For further … WebKaždá filmom obalená tableta obsahuje 150 mg idebenónu. Jadro tablety: mohohydrát laktózy, mikrokryštalická celulóza, sodná soľ kroskarmelózy, povidón K25, magnéziumstearát a koloidný oxid kremičitý. Film tablety: makrogol, poly (vinylalkohol), mastenec, oxid titaničitý, farbivo oranžová žlť (E110).
Raxone fachinformation
Did you know?
WebIntroduction: Leber's Hereditary Optic Neuropathy (LHON) causes a rapid and severe decrease in visual acuity. Raxone ® (Idebenone, Santhera) is the only drug to have a European Marketing Authorization for the treatment of this optic neuropathy. It can be proposed in the first months after the onset of this optic neuropathy, according to an … WebRaxone contains sunset yellow (E110) which may cause allergic reactions. Interaction with other medicinal products and other forms of interaction Data from in vitro studies have …
WebSep 9, 2015 · Raxone a ‘major breakthrough’ in mitochondrial disease treatment “Raxone represents a major breakthrough in mitochondrial disease treatment, and its approval paves the way for patients with LHON to be treated and to achieve a meaningful improvement of their visual acuity,” said Thomas Klopstock, MD, Professor for Neurology at the University … WebNov 8, 2024 · Raxone contains sunset yellow (E110) which may cause allergic reactions. 4.5 Interaction with other medicinal products and other forms of interaction Data from in vitro …
WebJun 23, 2024 · LEROS, a Phase 4 externally-controlled open-label intervention study, was designed to confirm the efficacy of Raxone in patients with LHON after 12 months of … WebMay 24, 2024 · Santhera Pharmaceuticals (SIX: SANN) announces that it has entered into an exclusive license agreement with Chiesi Farmaceutici, an international research-focused healthcare group (Chiesi Group), under which Chiesi Group will in-license Raxone® for the treatment of LHON for a total consideration of up to CHF 105 million (EUR 93 million), …
WebMay 22, 2014 · A total of 93.8% of Catena ® /Raxone ® -treated and 94.1% of placebo-treated patients experienced at least one Adverse Event (AE). Serious AEs were reported in 6.3% of Catena ® /Raxone ...
WebRaxone DMF, CEP, Written Confirmations, FDF, Prices, Patents, Patents & Exclusivities, Dossier, Manufacturer, Licensing, Distributer, Suppliers, News idebenone, 58186 ... theoretical win vs actual wintheoretical wisdomWeb- RAXONE (CAP) - PSUSA/00010412/202409 Applicant: Santhera Pharmaceuticals (Deutschland) GmbH PRAC Rapporteur: Amelia Cupelli . Scope: Evaluation of a PSUSA procedure . Action: For adoption of recommendation to CHMP . 13. Centrally authorised product(s) only . 14. Centrally authorised product(s) only theoretical wisdom examplesWebRaxone is a medicine used to treat visual impairment in adults and adolescents aged 12 years and over with Leber’s hereditary optic neuropathy (LHON), an inherited disease … theoretical withdrawal premiumWebTechnical details about Raxone, learn more about the structure, uses, toxicity, action, side effects and more theoretical wisdom and practical wisdomWebFeb 8, 2024 · Pratteln, Switzerland, February 8, 2024 – Santhera Pharmaceuticals (SIX: SANN) announces that it has secured a final reimbursement agreement with the French … theoretical wordsWebRaxone is not expected to affect your ability to drive or use . machines. Raxone contains lactose and sunset yellow (E110) • If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before . taking this medicinal product. • Raxone contains a colourant called “sunset yellow” (also called E110). theoretical wisdom vs practical wisdom